Randomized trialMedical2026
Analgesic effect of full-spectrum cannabidiol oil in burning mouth syndrome: randomized single-blind placebo trial.
Parise G.; Silvestre A.; Schussel J. · Oral surgery, oral medicine, oral pathology and oral radiology · 2026
Research summary
**Background & Methods**
This randomized, single-blind, placebo-controlled trial evaluated full-spectrum cannabidiol (CBD) oil in patients with burning mouth syndrome, a chronic oral pain condition with limited effective treatment options. Twenty-six patients (96% female, mean age 61.9 years) from a single-center orofacial pain clinic were randomly assigned to CBD oil (n=13) or placebo (n=13), with pain intensity assessed via visual analog scale and quality of life measured using the Oral Health Impact Profile-14.
**Key Findings**
• The CBD group demonstrated significant reductions in pain intensity and impact over time, with statistically significant between-group differences emerging from the third assessment onward (P < .001), while the placebo group showed no meaningful change.
• Oral health-related quality of life improved significantly in the CBD-treated group (P = .001), indicating functional and psychosocial benefits beyond pain reduction.
• The intervention demonstrated a favorable safety profile with no serious adverse events reported during the trial period.
**Dosage & Administration**
Not reported. The abstract does not specify the CBD dose, frequency of administration, treatment duration, or specific formulation characteristics beyond "full-spectrum CBD oil."
**Safety & Adverse Effects**
No serious adverse events were observed in either group. The abstract does not provide detailed information regarding mild or moderate adverse effects, tolerability, or specific safety monitoring parameters beyond general adverse event monitoring.
**Evidence Quality**
This study represents moderate-quality evidence with several limitations. The small sample size (n=26) limits statistical power and generalizability. The single-center design and predominately female population (96%) reduce external validity. Single-blinding (rather than double-blinding) introduces potential bias, particularly given the distinctive sensory characteristics of CBD oil that may allow patient unblinding. The abstract does not report treatment duration, dropout rates, or intent-to-treat versus per-protocol analyses. As a 2026 publication, additional peer-review scrutiny is warranted. Despite these limitations, the study provides preliminary evidence supporting CBD's potential role in burning mouth syndrome management and justifies larger, adequately powered, double-blind trials. The favorable safety profile is noteworthy given the chronic nature of this condition and typical patient age.
Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.
Journal
Oral surgery, oral medicine, oral pathology and oral radiology
Study type
Randomized trial
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed
More recent cannabis research
This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.